CIK 0001626971 · Non-accelerated filer<br>Smaller reporting company
Corvus Pharmaceuticals, Inc.
Sign in to watch- Ticker
- CRVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464670809
- Phone
- (650) 900-4520
- Business address
- 901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $50,475
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$50,475. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 24 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-04 | MILLER RICHARD A MD President and CEO | Grant or award · Stock Option (Right to Buy) | +1,000,000 | 1,000,000 | ||
| 2025-12-04 | Arcara Jeffrey Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2025-12-04 | LEA LEIV Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2025-10-02 | Moore David Scott Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2025-06-27 | ORBIMED ADVISORS LLC Director | Option exercise | +1,397,684 | $3.50 | $4.9M | 8,341,338 |
| 2025-06-27 | ORBIMED ADVISORS LLC Director | Sale | −1,176,332 | $4.16 | $4.9M | 7,165,006 |
| 2025-06-27 | ORBIMED ADVISORS LLC Director | Option exercise · Common Warrants (right to buy) | −1,397,684 | 0 | ||
| 2025-06-27 | Thompson Peter A. Director | Option exercise | +1,397,684 | $3.50 | $4.9M | 8,341,338 |
| 2025-06-27 | Thompson Peter A. Director | Sale | −1,176,332 | $4.16 | $4.9M | 7,165,006 |
| 2025-06-27 | Thompson Peter A. Director | Option exercise · Common Warrants (right to buy) | −1,397,684 | 0 | ||
| 2025-06-12 | Grais Linda Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2025-06-12 | CLARK IAN T Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2025-06-12 | Morrison Scott W Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2025-06-12 | Thompson Peter A. Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2025-06-04 | Jones William Benton See Remarks | Option exercise | +19,357 | $3.50 | $68K | 173,130 |
| 2025-06-04 | Jones William Benton See Remarks | Option exercise · Warrant (Right to Buy) | −19,357 | 0 | ||
| 2025-05-07 | MILLER RICHARD A MD President and CEO | Option exercise | +559,073 | $3.50 | $2.0M | 1,136,707 |
| 2025-05-07 | MILLER RICHARD A MD President and CEO | Option exercise · Warrant (Right to Buy) | −559,073 | 0 | ||
| 2025-04-08 | van den Broek Richard Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2024-12-20 | Arcara Jeffrey Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 |
Page 3 of 15 · 286 trades